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ABSTRACT
Objective Eosinophilic oesophagitis (EoE) is a chronic
inflammatory condition of the oesophagus with limited
treatment options. No previous transgenic model has
specifically targeted the oesophageal mucosa to induce
oesophageal eosinophilia.
Design We developed a mouse model that closely
resembles EoE by utilising oxazolone haptenation in mice
with transgenic overexpression of an eosinophil poietic
and survival factor (interleukin (IL)-5) in resident
squamous oesophageal epithelia.
Results Overexpression of IL-5 in the healthy
oesophagus was achieved in transgenic mice (L2-IL5)
using the squamous epithelial promoter Epstein–Barr
virus ED-L2. Oxazolone-challenged L2-IL5 mice
developed dose-dependent pan-oesophageal
eosinophilia, including eosinophil microabscess formation
and degranulation as well as basal cell hyperplasia.
Moreover, oesophagi expressed increased IL-13 and the
eosinophil agonist chemokine eotaxin-1. Treatment of
these mice with corticosteroids significantly reduced
eosinophilia and epithelial inflammation.
Conclusions L2-IL5 mice provide a novel experimental
model that can potentially be used in preclinical testing
of EoE-related therapeutics and mechanistic studies
identifying pathogenetic features associated with
mucosal eosinophilia.
INTRODUCTION
Eosinophilic oesophagitis (EoE) is a chronic allergic
gastrointestinal disease manifest by dysphagia and
food impaction in adults as well as a collection of
symptoms previously associated with gastro-
oesophageal reflux disease in children.1 2
Diagnostic criteria focus on clinical and histopatho-
logical assessments that centre on the presence of
eosinophils in the oesophageal epithelia.1
EoE occurs as a result of a hypersensitivity
response in the oesophageal mucosa. As such, cur-
rently available mouse models of EoE have been
derived by the direct allergen challenge of oesopha-
geal mucosae following sensitisation in systemic
transgenic mice.3–7 This approach derives from
observations that elimination of food allergens bene-
fits clinicopathological aspects of the disease,8 9 and
there is increased local expression of eosinophil
agonists, including interleukin (IL)-5 and eotaxin
chemokines.5 10–14 These mouse models amplify the
local response with systemic overexpression of the
eosinophil agonist cytokine IL-5 (CD2-IL5)5 or
ectopic constitutive expression in non-oesophageal
organs such as the lung (CC10-IL-13)15 and small
intestine (FABPi-IL-5, FABPi-Eotaxin).4 16
In the present study, we took an alternative
approach and specifically targeted IL-5 expression
to the oesophageal squamous epithelia using the
Epstein–Barr virus ED-L2 (EBV-ED-L2) gene pro-
moter.17 These data showed that constitutive
Significance of this study
What is already known on this subject?
▸ EoE is an allergic disease characterised by
Th2-polarised immune events.
▸ EoE inflammation is characterised by increased
numbers of eosinophils, eosinophil
microabscess formation and superficial layering
of the eosinophils in the oesophageal epithelia.
▸ Therapeutic strategies targeting oesophageal
eosinophilia lead to the abatement of this
inflammation.
What are the new findings?
▸ The squamous cell-specific promoter EBV-ED-L2
allows for ectopic constitutive expression of
heterologous genes in transgenic mice.
▸ Oesophageal epithelial overexpression of IL-5
(L2-IL5) correlates with oesophageal-specific
inflammatory events.
▸ Steroid treatment of oxazolone-challenged
L2-IL5 mice ameliorates the induced
inflammation.
How might it impact on clinical practice in
the foreseeable future?
▸ Development of an allergen-naive mouse EoE
model that specifically targets the oesophageal
epithelia provides a unique and user-friendly
preclinical system with which to define
underlying immune mechanisms that mediate
oesophageal inflammation that can be targeted
for therapeutic interventions.
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squamous oesophageal epithelial-specific overexpression of IL-5
(L2-IL5 transgenic mice) resulted in a baseline oesophageal
eosinophilia. On sensitisation and subsequent topical oesopha-
geal challenge of L2-IL5 mice with oxazolone, a molecule
known to induce T-helper cell (Th) type 2 responses in other
organs, mice developed key histopathological features consistent
with human EoE. These features include epithelial hyperplasia
and eosinophilic microabscesses that erupt through the epithe-
lium into the oesophageal lumen. This model will provide inves-
tigators with a novel system to determine mechanistic pathways
and test preclinical therapeutics focusing on EoE.
MATERIALS AND METHODS
Generation of L2-IL5 transgenic mice
The expression of a 5.5 kb IL-5 complementary DNA/genomic
fusion gene18 was driven using a promoter derived from the
EBV-ED-L2 gene17 19 (figure 1). Age-matched wild-type C57BL/
6J littermate mice were used as controls for all experiments.
Mouse studies were approved by the University of Colorado
Denver Institutional Animal Care and Use Committee.
Induction of experimental oesophageal eosinophilia in
L2-IL5 mice by sensitisation and topical challenge with
oxazolone
A mouse model of oesophageal inflammation was established
using a 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (OXA;
Sigma, St Louis, Missouri, USA) contact hypersensitivity protocol
(figure 2). See supplementary materials (available online only).20
Dexamethasone treatment
Dexamethasone treatments were performed as described21
(figure 2). See supplementary materials (available online only).
Tissue collection and histological analysis
Tissues were fixed with 10% neutral buffered formalin and pro-
cessed in preparation for being paraffin embedded.21 Serial sec-
tions from these paraffin tissue blocks were cut (5 μm) and were
either stained with H&E or subjected to histological assessments
(see table 1) or immunohistochemistry using either an anti-
mouse eosinophil major basic protein (MBP)-specific rat mono-
clonal antibody,22 the Ki67 monoclonal antibody to assess cell
proliferation.23 Quantification of either MBP-1 (ie, eosinophils)
or Ki67 immunopositive cells are presented as numerical
averages of nine non-overlapping high-power fields (0.26 mm2)
per oesophagus (three distal, three mid and three proximal).
Slides were also subjected to immunofluorescence analysis. See
supplementary materials (available online only).
Cell isolation, quantification and flow cytometric and
fluorescence-activated cell-sorting analysis
Leucocytes from tissue sources including spleen, bone marrow,
peripheral blood and oesophagus were isolated as previously
described.21 23 24 See supplementary materials (available online
only).
Single-cell suspensions were stained on ice with cell type-
specific antibodies as previously described.21 See supplementary
materials (available online only).
RNA isolation and real-time reverse transcription PCR
Whole oesophageal tissue total RNA was prepared using
RNeasy mini kits (Qiagen, Valencia, California, USA), cDNA
synthesis (Applied BioSystems) and real-time reverse transcrip-
tion (RT)–PCR with Taqman gene expression assays Taqman
probes (Applied Biosystems) as previously described.21
Cytokine assessments of oesophageal tissueand blood
serum
Oesophagi and blood serum were assessed for cytokine produc-
tion as previously described.21 23
Figure 1 IL-5 transgenic mice utilising the Epstein–Barr virus ED-L2
(EBV-ED-L2) gene promoter generate animals that ectopically express
high levels of IL-5 from squamous epithelium of the oesophagus. (A)
An EBV-ED-L2 promoter fragment was cloned upstream of mouse IL-5
cDNA:genomic fusion gene that includes the complete IL-5 ORF and all
of the IL-5 genomic exons/introns without any endogenous upstream
cis-regulatory sequences. (B) IL-5 transgene expression (ie, mRNA)
assessed in squamous epithelial-derived tissues (reverse transcription
(RT)–PCR) demonstrates a unique pattern of induced ectopic expression
with maximum in the oesophagus. IL-5 mRNA levels in a given tissue
were initially normalised to 18S within each sample and expression
levels among tissues examined are reported as fold increase relative to
IL-5 expression in liver (ie, a tissue devoid of squamous-epithelium). (C)
IL-5 mRNA (oesophageal) and protein (oesophageal and circulating)
levels in L2-IL5 mice are characteristic of a pattern of localised IL-5
overexpression with displacement into systemic circulation. Oesophagi
from wild-type and L2-IL5 mice (10–30 weeks of age) were processed
for whole tissue RNA and assessed for IL-5 expression by RT-PCR. IL-5
levels were normalised to 18S within each sample and then reported as
fold-increase relative to wild-type levels at 10 weeks of age. IL-5
secretion from the oesophagus was assessed by ELISA from
supernatants of whole oesophageal explant cultures and circulating
IL-5 levels were determined from serum samples derived from blood
recovered from 10-week-old wild-type and L2-IL5 mice. These data are
expressed as means±SEM of five to six individual mice per group.
*p≤0.05, **p≤0.01, ***p≤0.001.
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Statistical analysis
Statistical analyses of data outcomes were performed using a
two-tailed Student’s t test. Data are expressed as means±SEM.
A p value of 0.05 or less was considered statistically significant,
although in some cases higher levels of significance are noted
and described in the figure legends when applicable.
RESULTS
Transgenic mice constitutively express IL-5 from
oesophageal squamous epithelial cells
A mouse model replicating inflammatory changes linked with
EoE was developed by generating transgenic mice (L2-IL5) that
constitutively express the eosinophil agonist cytokine IL-5 in
resident oesophageal stratified squamous epithelial cells (figure
1A). The tissue/cell specificity of ectopic IL-5 expression in
these mice was achieved using an Epstein–Barr virus (ED-L2)
promoter fragment that was previously shown to limit
heterologous gene expression to tissues/organs that contain
squamous epithelium.17 RT–PCR assessments of IL-5 gene
expression in L2-IL5 mice thus demonstrated that transgene
expression is limited to the tongue, oesophagus and foresto-
mach, with the highest level of IL-5 expression found in the
oesophagus (figure 1B). These RT–PCR assessments also
showed that oesophageal IL-5 expression in L2-IL5 mice did
not vary as a function of postpartum age (wild-type control
animals displayed little to no IL-5 expression at any time point
examined), remaining at constitutively high levels from
10 weeks to 30 weeks of age (figure 1C).
Production of IL-5 protein from the oesophagus was con-
firmed by ELISA assessment of culture supernatants derived
from oesophageal explants. Consistent with observed levels of
messenger RNA/gene expression, IL-5 secretion by oesophageal
explants also did not vary as a function of postpartum age
(figure 1C). Similar to a pulmonary model of IL-5 overexpres-
sion,25 serum IL-5 in the L2-IL5 mice was elevated (figure 1C).
Systemic and oesophageal IL-5 overexpression induce
eosinophilia in haematopoetic, peripheral and oesophageal
compartments
Elevated IL-5 levels in the peripheral circulation of 10-week-old
L2-IL5 mice were associated with significant increases (ie, rela-
tive to wild-type control animals) in eosinophil levels in haem-
atopoietic compartments including the bone marrow (figure 3A)
and spleen (figure 3B). In both cases cytospin assessment of
DiffQuick (commercial Romanowsky) stained slides revealed
cells with the characteristic appearance of eosinophil-committed
progenitor cells. Additional evidence of extramedullary haem-
atopoiesis in L2-IL5 mice also included splenomegaly and
splenic eosinophil clusters by routine H&E histology (see sup-
plementary figure S1, available online only). Assessments of per-
ipheral blood (figure 3C) showed that unlike the nominal
circulating levels of white blood cells and eosinophils found in
wild-type control animals (1.37×10−6 cells and 0.01×10−6
eosinophils, respectively), L2-IL5 mice displayed significant
increases in both white blood cells and peripheral eosinophil
numbers (5.9×10−6 cells and 1.8×10−6 eosinophils, respect-
ively); DiffQuick (commercial Romanowsky) stains of cytospins
showed that these cells displayed morphologies characteristic of
mature peripheral eosinophils.
Detailed assessments of the oesophagi of L2-IL5 mice showed
that the localised squamous epithelial cell expression of IL-5
resulted in prominent oesophageal tissue eosinophilia (figure 3D).
In particular, MBP-1 demonstrated a significant increase in
tissue infiltrating eosinophils in this compartment relative to
wild-type control animals (4.3±0.6 eosinophils/400× high
powered field (hpf) (in all microscopic examinations,
hpf=0.26mm2) versus 0.6±0.2 eosinophils/400× hpf. These
assessments of stained tissue sections were confirmed by
fluorescence-activated cell-sorting analyses of disassociated cells
recovered from oesophagi (figure 3D). These data also showed
that the oesophagus of an L2-IL5 mouse displays a significant
increase (ie, relative to wild type) in resident eosinophils (ie,
CD45+, Ly6G−, MHC II−/dim, Siglec F+ cells; 5.7×10−3 vs
0.16×10−3) whose appearance on DiffQuick (commercial
Romanowsky) staining is that of mature eosinophilic metamye-
locytes. In addition, a small and moderate increase in the pres-
ence of neutrophils (CD45+, CD11b+, Ly6G+; 0.14×10−3 vs
0.017×10−3), dendritic cells (CD45+, CD11c+, MHCII+;
0.38×10−3 vs 0.23×10−3), macrophages (CD45+, CD11b+,
MHCII+; 2.12×10−3 vs 0.82×10−3), CD4+ (2.4×10−3 vs
0.63×10−3) and CD8+ (0.59×10−3 vs 0.13×10−3)
Figure 2 Schematic timeline representing the
4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (OXA) sensitisation/
topical challenge model of delayed contact hypersensitivity. On day 0
of the OXA hypersensitivity protocol, a 2 cm×2 cm area of abdominal
skin of anaesthetised experimental animals was shaved and OXA was
applied to the skin surface (150 ml of a 3% (w/v) solution of OXA in
4:1 acetone-olive oil vehicle) to initiate the sensitisation phase of the
protocol.20 Sensitised mice received topical OXA challenges of the
oesophagus by gavage (p.c.) on protocol days 5, 8 and 12 with a 1%
(w/v) solution of OXA in 30% ethanol/olive oil vehicle into the proximal
oesophagus. Vehicle control animals (either wild-type or L2-IL5 mice)
were sensitised as noted above and challenged with 4:1 acetone-olive
oil vehicle alone. All mice were assessed 24 h following the last OXA
challenge (protocol day 13). Additional groups of mice were
concurrently treated with the corticosteroid dexamethasone (DEX) by
intraperitoneal (i.p.) injection of mice (10 mg/kg of body weight) during
the topical OXA challenge phase (protocol days 5, 8, 10 and 12);
control animals receiving intraperitoneal injections of saline vehicle
alone.
Table 1 Epithelial Histology Scoring Tool
Epithelial histology scoring tool Score
Eosinophilic clusters/abscesses 0=Absent
1=Present
Lymphoplasmacytic infiltrates 0=Absent
1=Present
Hyperkeratosis 0=Absent
1=Present
Dilated intercellular spaces 0=Absent
1=Present
Basal zone hyperplasia 0=≤25% Epithelial thickness
1=25–50% Epithelial thickness
2=50–75% Epithelial thickness
3=>75% Epithelial shickness
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T lymphocytes were identified by flow cytometry in the oesoph-
agi of L2-IL5 mice compared to wild-type controls. Mast cells
were assessed by alcian blue pH2.5 immunohistochemistry and
were not considered a significant component in the oesophagi
of L2-IL5 mice.
OXA sensitisation and oesophageal challenge of L2-IL5 mice
resulted in eosinophil-dominated oesophageal inflammation
consistent with EoE
Previous studies utilising OXA-induced delayed type hypersensi-
tivity reactions in the large intestine and skin have successfully
induced a robust Th2 and eosinophil-associated inflammatory
pathology.26 27 We hypothesised that a localised delayed
hypersensitivity reaction induced in mice predisposed to eosino-
philic oesophageal inflammation (ie, L2-IL5 animals) would
provide the necessary immune-mediated response to replicate
the histopathologies characteristically found in EoE patients.
L2-IL5 mice were sensitised with OXA and then subjected to a
topical OXA challenge of the oesophagus to induce a localised
oesophageal delayed hypersensitivity response (figure 2). OXA
sensitisation and topical oesophageal challenge of wild-type
mice induced a nominal increase in oesophageal epithelial histo-
pathology relative to vehicle control animals that did not
achieve statistical significance (figure 4A,B). In contrast, OXA
sensitisation and topical oesophageal challenge of L2-IL5
animals resulted in histopathological changes of the oesophageal
Figure 3 Constitutive expression of IL-5 from the squamous epithelium of L2-IL5 elicits the expansion of the eosinophilopoietic compartments of
bone marrow and spleen, an increase in circulating eosinophil numbers and an oesophageal eosinophilia. Flow cytometric analysis in combination
with fluorescence-activated cell sorting (FACS) was performed to identify and quantify the induced eosinophilia occurring in L2-IL5 mice. Regardless
of the tissue/compartment examined eosinophils were identified through sequential gates initially focusing on forward versus side scatter before
employing specific gates based on the presence/absence of unique cell surface markers (ie, CD45+, Ly6G−, MHCII−/dim, SiglecF+). Therefore,
eosinophils in (A) bone marrow, (B) spleen, (C) peripheral blood and (D) oesophagus were identified and quantified in 10-week-old L2-IL5 mice
relative to wild-type controls. These cells were subsequently subjected to FACS and eventually cell differential analysis of DiffQuick (commercial
Romanowsky) stained cytospin preparations of the sorted cell populations, identifying eosinophils in each of these compartments/tissues. These data
are expressed as means±SEM of five to six individual mice per group. *p≤0.05 and ***p≤0.001.
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epithelium that were significantly higher than either those dis-
played by L2-IL5 animals treated with vehicle alone or
OXA-sensitised/challenged wild-type mice (figure 4C–E).
Representative photomicrographs of H&E oesophageal sections
demonstrated the induced expansion of the oesophageal epithe-
lium and inflammatory cell infiltrate occurring in OXA-treated
L2-IL5 mice (figure 4D,E) relative to either vehicle-treated
L2-IL5 animals (figure 4C) or vehicle versus OXA-treated wild-
type mice (figure 4A vs B, respectively), findings confirmed in
histopathology scores (figure 4F).
The extent of the induced oesophageal eosinophilia and evi-
dence of eosinophil degranulation was determined by immuno-
histochemical detection of the eosinophil secondary granule
MBP-1.21 These immunohistochemical assessments revealed that
OXA-treated wild-type mice displayed mild tissue eosinophilia
relative to the virtual absence of eosinophils in
Figure 4 4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one (OXA)
sensitisation and topical oesophageal challenge of L2-IL5 mice results
in histopathological changes consistent with those observed in humans
with eosinophilic oesophagitis (EoE). H&E stained sections of
oesophagus were evaluated and representative photomicrographs are
presented from wild-type animals treated either with (A) vehicle or (B)
OXA and L2-IL5 mice treated either with (C) cehicle or (D, E) OXA. (F)
The peak level of inflammation (epithelial histopathology score) in each
group of mice was determined using an algorithm described in the
supplementary materials (available online only) and expressed as group
mean data±SEM. Scale bar represents 100 μM. These data are
representative of three separate experiments with five to nine individual
mice per group. **p≤0.01. Figure 5 4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one (OXA)
sensitisation and topical oesophageal challenge of L2-IL5 mice results
in eosinophilic histopathological changes consistent with those
observed in humans with eosinophilic oesophagitis (EoE). Oesophageal
eosinophil infiltration and localised degranulation were determined by
immunohistochemistry using a rat monoclonal anti-mouse major basic
protein (MBP) antibody. Stained oesophageal sections were evaluated
and representative photomicrographs are presented from wild-type
animals treated either with (A) vehicle or (B) OXA and L2-IL5 mice
treated either with (C) vehicle or (D) OXA. The eosinophilic
microabscess characteristic of this model (and human EoE) is shown in
(E) as well as (F) where a microabscess has erupted through the
squamous epithelial barrier of the oesophagus. (G) A quantitative
assessment of the oesophageal eosinophil infiltrate in each group of
mice was determined across nine high powered field (hpf ) of view
(three distal, three mid and three proximal) and expressed as group
mean data of the eosinophil density (ie, eosinophils/400× hpf )±SEM.
Scale bar represents 100 μM. These data are representative of three
separate experiments with five to nine individual mice per group.
*p≤0.05, **p≤0.01. ***p≤0.001. p Values not linked with
brackets indicate significance relative to L2-IL5 mice treated with
vehicle alone.
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vehicle-alone-treated wild-type animals (figure 5A,B). In add-
ition, these data showed that while the eosinophilia occurring in
L2-IL5 vehicle-alone-treated mice (figure 5C) was statistically
larger than those observed in wild-type animals, this response
was dwarfed by the induced eosinophilia and associated
degranulation occurring in OXA-treated L2-IL5 mice (figure
5D–F). The identity of MBP-1+ cells in OXA-treated L2-IL5
mice as exclusively eosinophil lineage in origin was confirmed
histologically by double immunofluorescence staining of
oesophageal tissue sections for Siglec F and MBP-1 (see supple-
mentary figure S2, available online only). The extent of induced
eosinophilia in wild-type versus L2-IL5 OXA-treated mice was
quantified (figure 5G) by detailed examination of tissue sections
(n=5–10/cohort) as the mean number of MBP-1+ cells/400×
hpf. These data showed that wild-type (vehicle control or
OXA-treated) and vehicle control L2-IL5 mice displayed only a
nominal oesophageal eosinophilia (averaged over the total
oesophageal length) relative to the induced eosinophilia occur-
ring in OXA-treated L2-IL5 mice. Quantification of induced
tissue eosinophilia occurring in OXA-treated L2-IL5 mice
demonstrated a longitudinal gradient that occurred with a statis-
tically higher density of eosinophils in distal oesophagi (figure
5G). No significant change in other leucocyte populations was
observed following OXA challenge of L2-IL5 mice.
The spatial pattern of the observed eosinophilia occurring in
OXA-treated L2-IL5 mice was also particularly noteworthy
because of its similar pattern to what has been described in EoE
patients. In particular, a dense epithelial and lamina propria
eosinophilia accompanied by eosinophil degranulation occurred
in L2-IL5 mice that appeared more at the surface relative to the
underlying subepithelial layers (figure 5D). In addition, eosino-
philic microabscess formation was evident (figure 5E), which
appeared to erupt through the epithelium into the oesophageal
lumen (figure 5F).
Oesophageal inflammation occurring in OXA-treated L2-IL5
mice is characterised by cell proliferation of the squamous
epithelial basal zone
Squamous epithelial hyperplasia, a key feature associated with
human EoE, was demonstrated to occur as part of the
eosinophil-dominated inflammation in OXA-treated L2-IL5
mice. Basal zone epithelial cell proliferation, measured by Ki67
immunohistochemistry, was significantly increased in
OXA-treated L2-IL5 mice relative to wild-type control mice
treated with either vehicle alone or OXA as well as L2-IL5 mice
treated with vehicle alone (figure 6A–D). Quantification of
Ki67+ cell numbers as the mean of nine or more 400× hpf
derived from five to 10 mice per group demonstrated that the
squamous epithelial proliferation observed in OXA-treated
L2-IL5 mice was statistically higher than that observed in
L2-IL5 animals treated with vehicle alone (figure 6E). Increases
in epithelial proliferation were not observed comparing vehicle
alone versus OXA-treated wild-type animals with both these
groups displaying the same level of proliferation as observed in
L2-IL5 mice treated with vehicle alone (figure 6E). Similar to
human EoE, a gradient of proliferation within the squamous
epithelium (ie, localised hyperplasia) was uniquely observed in
the oesophagus of OXA-treated L2-IL5 mice. In particular,
those epithelial cells in contact with the oesophageal basement
membrane (basal zone) differentially stained as Ki67+, encom-
passing 50–75% of the total epithelial thickness of OXA-treated
L2-IL5 mice (figure 6F). In addition, increased proliferation of
cells localised within the lamina propria could be observed
(figure 6D).
Increases in oesophageal IL-5, IL-13 and eotaxin-1 levels
characterised the immune microenvironment of OXA-treated
L2-IL5 mice
Gene expression in the oesophagi of OXA-treated L2-IL5
mice was assessed to determine the induced polarisation of the
immune microenvironment of this model system. RT–PCR
assessments of targeted Th1 versus Th2 cytokine gene expres-
sion revealed that the oesophagi of OXA-treated L2-IL5 mice
differentially expressed IL-5 and IL-13 (Th2 cytokines) relative
to the Th1 cytokine profile, which remained unchanged (figure
7A). Moreover, oesophageal explant cultures derived from
Figure 6 4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one (OXA)
sensitisation and topical oesophageal challenge of L2-IL5 mice results
in squamous epithelial changes indicative of inflammatory events
similar to those observed in human subjects with eosinophilic
oesophagitis (EoE). Epithelial cell proliferation and expansion of this
compartment was determined by immunohistochemistry assessing for
the presence of the marker Ki67. Stained oesophageal sections were
evaluated and representative photomicrographs are presented from
wild-type animals treated either with (A) vehicle or (B) OXA and L2-IL5
mice treated either with (C) vehicle or (D) OXA. (E) The density of
Ki67+ cells in the epithelial layer was determined as the mean value
(evaluating nine high powered fields of oesophagi (three distal, three
mid and three proximal) recovered from 5–10 mice)±SEM. (F) The peak
level of basal zone hyperplasia in each group of mice was determined
using an algorithm described in the supplementary materials (available
online only) and expressed as group mean data±SEM. Scale bar
represents 100 μM. These data are representative of three separate
experiments with five to nine individual mice per group. **p≤0.01,
***p≤0.001.
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OXA-treated L2-IL5 mice were shown to secrete significantly
higher levels of eotaxin-1 (but not eotaxin 2) compared to
explants of either wild-type vehicle-alone or OXA-treated
animals as well as explants derived from vehicle-alone-treated
L2-IL5 mice (figure 7B).
Infiltrating oesophageal eosinophils from OXA-treated
L2-IL5 display cell surface phenotypes characteristic of
mature tissue resident granulocytes
Oesophageal eosinophils from OXA-treated L2-IL5 mice were
compared by flow cytometry relative to eosinophils derived
from control L2-IL5 animals treated with vehicle alone.
Eosinophils were defined based on a granulocyte scatter-based
gate and a surface profile of CD45+, Ly6G−, MHCII−/dim and
SiglecF+ (figure 8). Haematological staining and cell differential
analysis of these sorted populations confirmed the identity of
these cells as mature granule protein-rich eosinophils. Resident
oesophageal eosinophils from OXA-treated L2-IL5 mice showed
substantially increased expression of cell surface markers CCR3
and Ly6C relative to eosinophils from oesophagi of L2-IL5
mice treated with vehicle alone (figure 8). However, no changes
were observed in levels of the other surface markers assessed,
including CD11b, CD11c, CD103, F4/80, CD44, CD34, Sca-1
(Ly6A/E) and CD69 (figure 8); IL-5Rα remained close to
undetectable in both eosinophil populations (data not shown).
Oesophageal inflammation in OXA-treated L2-IL5 mice was
steroid responsive
The successful treatment of EoE patients with corticosteroids1 28
led us to determine if the eosinophilic oesophageal inflamma-
tion of the OXA-treated L2-IL5 model of oesophagitis was atte-
nuated by corticosteroid administration. A dexamethasone
administration protocol was overlaid onto the OXA treatment
timeline, delivering dexamethasone by intraperitoneal injection
(vehicle alone served as a negative control) throughout the OXA
challenge phase of this inflammatory model (figure 2). Those
studies demonstrated that administration of dexamethasone sig-
nificantly reduced epithelial inflammation and eosinophilia in
OXA-treated L2-IL5 mice (figure 9). In particular, H&E stained
sections (figure 9A) revealed that dexamethasone administration
significantly reduced the proinflammatory cell infiltrate and
tissue oedema associated with this model; quantification of this
epithelial inflammation demonstrated the significance of this
corticosteroid-mediated decrease (figure 9B,C).
Immunohistochemical detection of tissue infiltrating eosinophils
(ie, MBP-1+ leucocytes) also showed that oesophagi of
OXA-treated L2-IL5 mice had evidence of a dense eosinophil
infiltrate (figure 9D,E) that was significantly reduced with dexa-
methasone administration compared to L2-IL5 mice adminis-
tered vehicle alone (figure 9F). Finally, assessments of squamous
epithelial hyperplasia by Ki67 immunohistochemistry showed
Figure 7 The induced eosinophilic oesophageal inflammation occurring in 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (OXA)-treated L2-IL5 mice
is characterised by a T-helper cell (Th) type 2 predominated cytokine expression profile accompanied by overexpression of the eosinophil agonist
chemokine eotaxin-1 but not eotaxin-2. (A) Total RNA derived from whole oesophagi of OXA-treated wild-type versus L2-IL5 mice were used as the
starting templates for Taqman based real-time reverse-transcription PCR assessments of expression from genes encoding cytokines characteristic of
Th1 versus Th2 immune responses. Expression levels were normalised within each group relative to the levels of 18S ribosomal RNA before
determination of fold increase relative to observed levels in the oesophagi of OXA-treated wild-type mice. Individual values are expressed as group
means±SEM *p≤0.05, ***p≤0.001. (B) Eotaxin-1 and 2 expression levels derived from the oesophagi of each group of mice were determined by
ELISA of supernatants derived from explants cultured for 24 h. These data are representative of two separate experiments and are shown as mean
values±SEM of three to five individual mice per group. *p≤0.05, ***p≤0.001.
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that dexamethasone treatment led to a statistically significant
decline in the expanded proliferating basal zone characteristic of
this model (figure 9G,H,I).
DISCUSSION
Clinical studies and therapeutic trials investigating EoE
patients have documented a link between this disease and eosi-
nophils. Indeed, these investigations led to a consensus regard-
ing the definition of clinical and pathological descriptions of
EoE, diagnostic criteria and treatment guidelines for
patients.1 28 The development of animal models and transla-
tional studies to identify eosinophil-specific mechanisms elicit-
ing, and/or contributing to, disease pathologies has led to key
findings regarding the pathogenesis and therapeutic targets.
Mouse models of eosinophilic diseases have been particularly
valuable because of the availability of eosinophil-detecting
reagents (eg, mouse-specific antibodies), the availability of tar-
geted genetic aberrations (eg, transgenic overexpression and
ablation (knockouts) of specific genes of interest), and the
ability to perform complete assessment of endpoint patholo-
gies such as measures of physiological parameters, remodelling
and postmortem histopathology.18 21 25 29–31 Therefore,
together with the increasing understanding of immune
responses in the mouse and the realisation of how similar
these immune responses are with events occurring in patients,
these models have provided needed insights into human EoE,
including the mechanistic importance of IL-5 overexpres-
sion5 15 16 and the expression of eotaxins.5 11
Figure 8 Infiltrating oesophageal eosinophils from oxazolone in 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (OXA)-treated L2-IL5 display a cell
surface phenotype characteristic of mature tissue resident granulocytes. Oesophageal eosinophils are more mature following OXA exposure. (A) Flow
cytometric analysis of eosinophils (granulocyte gated, CD45+, Ly6G−, MHCII−/dim, SiglecF+ cells) in vehicle and OXA-treated L2-IL-5 oesophagi.
Surface markers CCR3 and Ly6C are increased with OXA challenge. Common markers with other myeloid populations are present in equal
abundance in both uninflamed and inflamed oesophagi. (B) These cells were subsequently subjected to fluorescence activated cell-sorting and
eventually cell differential analysis of DiffQuick (commercial Romanowsky) stained cytospin preparations of the sorted cell populations, identifying
eosinophils in each of these compartments/tissues. Data are representative of two separate experiments, with means±SEM of three to four
individual mice per group shown, *p≤0.05, **p≤0.01.
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Our present work that defines a novel mouse model of EoE
are based on a number of studies implicating the importance of
IL-5 in the pathogenesis of epithelial inflammation in allergic
diseases and specifically EoE. For instance, nasal, respiratory
and ocular epithelia secrete IL-5 in mouse models of allergic dis-
eases associated with mucosal eosinophilia.14 32–34 A number of
translational studies have also identified the oesophageal epithe-
lium of patients (captured by mucosal pinch biopsies) as a
source of localised increased IL-5 expression.14 16 32 35 The
source of this cytokine is thought to be infiltrating T cells or
eosinophils, but the lack of direct visualisation of all expressing
cells does not preclude the activated oesophageal epithelium as
an additional contributor to local IL-5 levels.14 36 That is, a
number of cells are probably contributing to the Th2 milieu of
the oesophagus in EoE patients, and we hypothesised that the
ectopic overexpression of IL-5 by oesophageal epithelial cells in
L2-IL5 mice replicates this localised exacerbation of Th2
immune responses.
Oesophageal studies in the mouse have bifurcated based on
the experimental strategies utilised to generate these models of
Figure 9 Corticosteroid treatment of in 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (OXA) sensitised/topical challenged L2-IL5 mice leads to the
attenuation of all histopathological metrics associated with this mouse model of human eosinophilic oesophagitis (EoE). H&E stained sections of
oesophagus (A, B) as well as sections subjected to major basic protein (MBP)-1 (D, E) and Ki67 (G, H) immunohistochemistry were evaluated and
representative photomicrographs are presented from OXA-treated L2-IL5 mice treated with either vehicle alone (saline) or dexamethasone (DEX).
Dexamethasone was administered to individual mice on protocol day 5, 8, 10 and 12 by intraperitoneal injection of 200 μg dexamethasone (Vedco,
St Joseph, Missouri, USA) suspended in 200 μl of saline (figure 2). Control mice received 200 μl of saline alone. (C) The peak level of inflammation
(epithelial histopathology score) in each group of mice was determined using an algorithm described in the supplementary materials (available
online only) and expressed as group mean data±SEM. (F) A quantitative assessment of the oesophageal eosinophil infiltrate in each group of mice
was determined and expressed as group mean data of the eosinophil density (ie, eosinophils/400× high powered field (hpf ) (evaluating nine hpf/
oesophagus; three distal, three mid and three proximal))±SEM. (I) The density of Ki67+ cells were determined as the mean value (evaluating nine
hpf/oesophagus; three distal, three mid and three proximal)±SEM. Scale bar represents 100 μM. Data are expressed as means±SEM derived from six
to 10 individual mice per group. **p≤0.01, ***p≤0.001.
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EoE: (1) Sensitisation/local challenge approaches in which wild-
type mice undergo a primary sensitisation event to allergen
(and/or a contact irritant) followed by a secondary topical chal-
lenge of the oesophagus with the same agent.3 6 7 (2)
Transgenic overexpression in mice of candidate inflammatory
genes identified from clinical studies of EoE patients.5 37
Although both of these approaches have provided valuable
insights regarding mechanisms of action, these models have not
been organ/tissue specific as transgene expression occurs outside
the oesophageal compartment (eg, lymphocyte/small intestinal
driven expression of IL-55 or pulmonary-derived IL-13,37 and
some features of the histopathology have not been demonstrated
as seen in human EoE. The development of the mouse model
used in our study targeted the oesophageal mucosa to overex-
press IL-5, thus representing a logical extension of results from
translational studies that have previously defined the Th2 mileu.
Subsequent use of this model with a local challenge led to key
histological, molecular and pharmacological features seen in
human EoE.
The relative difference in oesophageal pathologies occurring
in the transgenic line alone versus transgenic animals subject to
the sensitisation/oesophageal challenge model demonstrated the
interplay, and ultimately the importance, of concomitant
immune responses and eosinophil-mediated activities. In par-
ticular, even though squamous epithelial-specific IL-5 expression
alone, without sensitisation and challenge, (ie, L2-IL5 mice)
induced a significant oesophageal eosinophilia encompassing the
length of the oesophagus (ie, relative to wild-type-sensitised/
challenged wild-type mice), this eosinophilia was not accompan-
ied by the density of histopathological changes such as eosino-
philic microabscesses characteristic of EoE. Moreover, unlike
L2-IL5 mice subjected to sensitisation/oesophageal challenge,
the L2-IL5 vehicle or naive mice did not display evidence of
dilated intra-epithelial spaces, basal cell hyperplasia and prolifer-
ation of cells within the lamina propria. These observations
suggest that the presence of oesophageal eosinophils alone is a
necessary but not a sufficient event occurring in EoE. This con-
clusion suggests a parsimonious explanation of patients who
have a tissue eosinophilia consistent with EoE yet display either
no overt symptoms or symptoms inconsistent with an EoE diag-
nosis. In addition, the disconnect between co-stimulatory
inflammation and oesophageal eosinophilia may also explain the
apparent overlap between some patients with gastro-
oesophageal reflux disease. That is to say, in some patients, acid-
induced oesophageal inflammation may elicit a tissue eosino-
philia without providing the additional needed co-inflammatory
signals necessary for the development of EoE symptoms.
The validation that this compound model system is reflective
of human EoE was also demonstrated by both the oesophageal
expression of other significant inflammatory pathways that have
been linked with EoE in clinical and translational studies and
the steroid responsiveness of the induced pathologies occurring
in OXA-treated L2-IL5 mice. In particular, we demonstrated
that this mouse model displayed increased IL-5 expression and
the concomitant local expression of IL-13 and eotaxins.11 35
Therefore, unlike sensitisation/oesophageal challenge of the
wild-type mice, which elicits only nominal changes in the
oesophageal expression of inflammatory markers characteristic
of human EoE (ie, IL-13 and/or eotaxins), our compound
model of sensitisation/oesophageal challenge of L2-IL5 mice
specifically promotes high-level expression of inflammatory
markers characteristic of human disease.11 35 38 The observation
that this increase was not linked to either IL-5 transgene expres-
sion nor the sensitisation/oesophageal challenge alone, but
instead was the product of both events, suggests a relationship
exists between the robust oesophageal eosinophilia induced in
this system and the additional expression of these eosinophilia
agonists and/or inflammatory biomarkers characteristic of EoE.
In this current mouse model, we provide a detailed examin-
ation of not only the oesophageal mucosa but also the periphery
in a consistently ‘primed’ state; IL-5 levels are increased
throughout the naive, sensitisation and challenged states in a
fashion that may be reflective of the atopic condition EoE. As
peripheral eosinophilia may be a surrogate biomarker for thera-
peutic trials, such as corticosteroids39 and the anti-IL-5 antibody
therapy mepolizumab,40 41 this may offer another important
model feature. In recent consensus recommendations, it was
noted that a subpopulation of EoE patients develop peripheral
eosinophilia and this may correlate with tissue eosinophilia;
however, these changes should be considered alongside a
number of other factors.1 Therefore, while no single systemic
biomarker, including peripheral eosinophila, is reliable for EoE,
there is a subset of patients for whom the increased levels of sys-
temic eosinophilia found in our model may still be relevant. We
anticipate that the complexity of this disease and the limitations
of the mouse will require the generation of a number of models
like L2-IL5 replicating specific aspects of this disease in an
effort to understand EoE mechanistically.
While there are a number of significant similarities between
our L2-IL5 model and human EoE, there remain some obvious
differences. Examination of the inflammatory response in
human EoE includes that of smooth muscle infiltrating mast cell
and lamina propria eosinophil production of transforming
growth factor β as well as epithelial cell tumour necrosis factor
α production, our mouse model of EoE did not. In addition,
this model utilises a contact allergen, whereas it is thought
patients with EoE develop as an allergic response mainly to
food and environmental allergens. As with all animal models,
they remain just that, incomplete models of human conditions.
Clearly, this is often a shortcoming with virtually all animal
models due to immunological, biochemical and physiological
species differences. The observations surrounding the L2-IL5
mouse model provide a foundation for a number of future
studies that will address specific mechanisms linked with
oesophageal remodelling and dysfunction. Whereas this has
been addressed in some studies to date, in particular as it per-
tains to oesophageal fibrosis, additional insights have yet to be
gained. For example, the use of food allergens (as opposed to
OXA-initiated hypersensitivity) to initiate and perpetuate this
response will bring additional relevance to the overall model as
it relates to human EoE. Strategic approaches to elicit eosinophil
activation/degranulation in L2-IL5 mice will probably be add-
itional areas of study expected to improve the representative
character of this experimental approach of modelling human
EoE in the mouse.
The novelty of this mouse model of EoE has been addressed
through our reductionist approach of building on observations
of patients along with the mechanistic insights and technological
expertise of basic research scientists, thus allowing us to move
closer to an in-vivo model that closely represents the human
disease. We suggest that our creation of a novel model system
combining targeted gene expression in the oesophageal epithelia
with topical oesophageal challenge of sensitised mice will
provide a method with which to define further mechanisms of
eosinophil effector function, how these mechanisms integrate
with ongoing oesophageal inflammation and the impact of
novel therapeutics in these processes. Therefore, we expect that
studies of L2-IL5 mice will lead to a greater understanding of
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the pathophysiological role of eosinophils in barrier dysfunction
and remodelling in EoE, with an expectation of valid extrapola-
tion to human patients and the development/testing of novel
therapeutic approaches targeting this localised oesophageal
eosinophilia.
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